Cost-Effectiveness of Population DNA Screening in Singapore: BRCA Works, Lynch Syndrome Needs a Different Path

The Question Behind Every Screening Programme

Genomic screening is scientifically feasible long before it becomes economically sensible. Singapore’s health system operates under explicit cost-effectiveness thresholds, and the decision to scale DNA-based risk detection depends on evidence that benefits justify the investment. A 2026 cost-utility analysis published in the Journal of Clinical Oncology provides one of the clearest Asian data points yet, comparing population-based germline testing strategies for hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS).

BRCA1/2 Population Testing Crosses the Threshold

The study’s central finding is that population-based BRCA1/2 testing for cancer-unaffected women aged 30 is the optimal strategy, with an incremental cost-effectiveness ratio of S$50,541 per quality-adjusted life-year—comfortably below Singapore’s willingness-to-pay threshold of S$75,000 per QALY. The probability of cost-effectiveness is 99.93%, and the strategy averts approximately one additional cancer per 1,000 women tested. Implementation would require an additional S$1.69 million annually and would identify 182 additional BRCA1/2 carriers per annual cohort.

Lynch Syndrome: A Different Economic Calculus

The picture changes for Lynch syndrome. Population-based germline testing for LS is not cost-effective at the same threshold, with an ICER of S$179,564 per QALY. Family-history-guided testing approaches cost-effectiveness but carries substantial decision uncertainty. That uncertainty resolves when cascade testing is extended to second-degree relatives, bringing the ICER down to S$63,809 per QALY. The lesson is that the value of LS screening is highly sensitive to operational choices—particularly surveillance adherence and the reach of family-based testing.

Why the Difference Matters for Policy

The divergence between BRCA and LS is not a scientific failure; it is a signal that genomic screening must be syndrome-specific rather than generic. BRCA testing benefits from a relatively well-defined intervention pathway—enhanced surveillance and risk-reducing surgery—that produces measurable downstream savings. LS screening, by contrast, depends on colonoscopy adherence and the willingness of relatives to participate in cascade testing, both of which are behavioural and system-level variables rather than purely clinical ones.

The Equity Dimension of Cost-Effectiveness

Cost-effectiveness analyses often obscure distributional questions. A strategy can be cost-effective in aggregate while leaving high-risk subgroups under-served. Singapore’s analysis explicitly models surveillance adherence and cascade uptake, recognising that economic value is realised only when patients actually complete the downstream pathway. This is particularly relevant for LS, where the benefit of testing is contingent on relatives accepting colonoscopy and other surveillance interventions.

From Evidence to Implementation

The study’s authors recommend evaluating multigene hereditary cancer panels that integrate LS-associated genes alongside BRCA1/2, leveraging shared laboratory and counselling infrastructure. For Singapore, the economic evidence points toward a tiered approach: population-based BRCA testing as a near-term priority, family-history-guided LS testing with extended cascade reach, and continued investment in the counselling and surveillance capacity that determines whether genomic screening delivers on its clinical promise.